Targeted treatment of iron deficiency in prolonged critical illness: an opportunity to improve survival or not?
- PMID: 34074323
- PMCID: PMC8170975
- DOI: 10.1186/s13054-021-03590-w
Targeted treatment of iron deficiency in prolonged critical illness: an opportunity to improve survival or not?
Conflict of interest statement
The authors declare that they have no competing interests.
Figures

Comment on
-
Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial.Crit Care. 2021 Feb 15;25(1):62. doi: 10.1186/s13054-020-03430-3. Crit Care. 2021. PMID: 33588893 Free PMC article. Clinical Trial.
References
-
- Lasocki S, Asfar P, Jaber S, Ferrandiere M, Kerforne T, Asehnoune K, Montravers P, Seguin P, Peoc'h K, Gergaud S, et al. Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. Crit Care. 2021;25(1):62. doi: 10.1186/s13054-020-03430-3. - DOI - PMC - PubMed
-
- Lasocki S, Puy H, Mercier G, Lehmann S, Hepcidane study g. Impact of iron deficiency diagnosis using hepcidin Mass Spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesth Crit Care Pain Med. 2017;36(6):391–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources